Tau protein concentrations were measured in the CSF of 23 patients with dementia of the Alzheimer type (DAT), 36 patients with multi-infarct dementia (MID), and 23 control subjects. Tau protein concentrations were significantly higher in patients with DAT than in controls (P < 0'001) and patients with MID (P < 0*001). A 
. There were no significant differences in age and sex between DAT and MID groups and controls.
The table shows the tau protein concentrations in CSF in the two groups of patients and controls. These were higher in patients with DAT than those with MID (P < 0-001) and control (P < 0-001) groups, whether expressed in pg/ml or in ng/g total protein.
The table shows the neuropeptide concentrations in CSF in the two groups of patients and controls. Substance P and somatostatin concentrations were lower in patients with DAT than in controls (P < 0-01), whereas neuropeptide Y concentration was not different between the three groups. Only somatostatin was significantly decreased in DAT compared with MID (P < 0-01).
In patients with DAT we found a good positive correlation between CSF tau protein and glucose concentrations (r = 0 79, P < 0 00 1). For cognitive function tests, there was a significant negative correlation between tau protein and the MSE test (r =-0 73, P < 0-001; (figure), but not with other neuropsychological tests (Blessed score, Rosen score). Moreover, a weak but significant correlation with the time course of DAT was found (r = 0 47, P < 0-05). We did not find significant correlations between CSF tau protein and somatostatin, substance P, or neuropeptide Y in patients with DAT, or between tau protein concentrations and age in the three groups studied.
Discussion
Because CSF offers the richest potential source of altered proteins in neurodegenerative diseases, we were interested in quantifying tau protein concentrations in CSF from In addition, a large difference between patients with DAT and MID was found. Thus there was a threefold increase in CSF tau protein concentrations in DAT compared with MID.
Increased tau concentrations have been described in brain extracts of patients with DAT,1' 18 this being most evident in associative brain regions involving particularly long corticocortical projections.38 This fact may be characteristic of DAT and it could be expressed clinically by functional cognitive deficits.'9 Thus we have found a significant negative correlation between the MSE test, but not with the Rosen score and Blessed dementia scale, and CSF tau protein levels in DAT patients. Because the MSE test examines patient cognitive function, the measurement of CSF tau protein might provide a correlation with the psychological symptoms and severity of disease. As in other studies,6 19 the appearance of tangles within the neocortex is a reliable marker for the presence of DAT and higher neocortical tangle densities are associated with more severe dementia.
Some studies3 19 that quantify tau protein in brain tissues indicate that its relation is with severity of dementia, but not with age of patients with DAT, and that its concentrations could distinguish DAT from processes occurring during normal aging. Vandermeeren et all' have found increased CSF tau values in patients with DAT and controls older than 60, but not in patients who had other diseases of the CNS. We did not find any correlation between CSF tau protein concentrations and age in patients and controls.
A recent study 20 In conclusion, increased concentrations of tau protein in CSF from patients with Alzheimer's disease were found. As tau protein is not found in blood or serum, its increased presence in CSF can reflect neuronal degeneration. Therefore, a simple test based on quantitative detection of tau protein in CSF fluid might be a useful marker in the diagnosis and assessment of severity in DAT. Further research is necessary to clarify the role of tau protein in patients with dementia and to establish the specificity and sensitivity of tau protein increases in DAT.
